Natalie Dakers, President & CEO, CDRD
Ms. Dakers is a leading figure in the Canadian biotechnology industry and currently serves as the Chief Executive Officer of the Centre for Drug Research and Development (CDRD). CDRD was set up to address the commercialization gap between early‐stage technologies arising out of university based research and investment opportunities. Ms. Dakers brings to CDRD many valuable years of experience in the commercialization of technology, licensing and intellectual property protection. Previously, Ms. Dakers was President & CEO of Neuromed Pharmaceuticals Inc., a private biopharmaceutical company developing drugs for chronic pain, anxiety, epilepsy and cardiovascular diseases. Prior to co‐founding Neuromed, Ms. Dakers was a senior manager for life sciences technology transfer at the University Industry Liaison Office (UILO) at the University of British Columbia. In this capacity, she was involved in the creation and spin‐off of more than a dozen start‐up high‐tech and biotech companies. Currently, Ms. Dakers is a board member of the Canada Foundation for Innovation (CFI) and the International Science and Technology Partnership Canada (ISTP Canada). Previously, Ms. Dakers also served on the Boards of Genome Canada, Genome BC, and the Michael Smith Foundation for Health Research. Ms. Dakers is an Adjunct Professor in UBC’s Faculty of Pharmaceutical Sciences and a member of the Council of Canadian Academies’ Expert Panel on Business Innovation. Ms. Dakers received a Peak Award for Performance and Excellence in 2004. In 2009, Ms. Dakers was the recipient of BIOTECanada’s Gold Leaf Award for Industry Leadership.
The Centre for Drug Research and Development
The Centre for Drug Research and Development is an independent, non‐profit organization with a focus on bridging the gap between academic discoveries in the health sciences and the development of new medicines to treat human disease. CDRD provides drug‐development expertise and facilities to enable researchers across Canada to develop promising drug candidates. Our organization draws on and develops discoveries made by scientists working in academic research and health institutions. Scientific and technical expertise guided by commercial insight allows our team to assess the chances that a discovery will result in a successful drug. We provide a collaborative framework through which drug development can become sustainable, cost‐effective, and advantageous to society.